Behaviour of Factors II, VII, IX, and X during Long-Term Treatment with Coumarin

E. A Loeliger; B van der Esch; M. J Mattern; A. S. A den Brabander

doi:10.1055/s-0038-1654962

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1963; 09(01): 074-089
DOI: 10.1055/s-0038-1654962

Originalarbeiten — Original Articles — Travaux Originaux

Schattauer GmbH

Behaviour of Factors II, VII, IX, and X during Long-Term Treatment with Coumarin

E. A Loeliger

¹Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands

,

B van der Esch

¹Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands

,

M. J Mattern

¹Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands

,

A. S. A den Brabander

¹Department of Haematology of the Clinic for Internal Medicine (Director: Prof. Dr. ]. Mulder), University Hospital, and the Thrombosis Service (Head: Dr. E.A. Loeliger), Leyden, The Netherlands

› Institutsangaben

Abstract

Summary

During long-term treatment with the long-acting coumarin derivative phenprocoumarol (marcoumar) no statistically significant difference in the depression of the activity of coagulation factors II, VII, IX, and X was found. The shorter-acting anticoagulants acenocoumarol (sintrom), warfarin sodium (coumadin), and dicoumarol, possibly lower factor IX somewhat less and factor X somewhat more than they do factors II and VII.

A 2.5-fold prolongation of the “prothrombin” time (using Owren ⁵ s human brain thromboplastin) and the same prolongation of the thrombotest time appear to correspond with a depression of all four factors from 100% down to approximately 20’%, the normal standard being a mixed population with a mean age of 29 years.

Separate determination of one of the four coagulation factors concerned is pointless; “prothrombin” time estimation, and more specifically thrombotest, still remain the most reliable methods for controlling the anti-vitamin K action of anticoagulants during long-term treatment.

Volltext

Referenzen

References
1 Bachmann F, Duckert F, Koller F. The Stuart-Prower factor assay and its clinical significance. Thrombos. Diathes. haemorrh. 02: 24 1958;
2 Bell W. N, Alton H. G. Brain extracts as a substitute for platelet suspensions in the thromboplastin generation-test. Nature (Lond) 174: 880 1954;
3 Biggs R, Bidwell E, Handley D. A, Macfarlane R. G, Trueta J, Elliot-Smith A, Dike G. W. R, Ash B. J. The preparation and assay of a Christmas-factor (factor IX) concentrate and its use in the treatment of two patients. Brit. J. Haemat. 07: 349 1961;
4 Esch van der B. Thesis, Leiden (to be published.
5 Folch J. Brain cephalin, a mixture of phosphatides. Separation from it of a phosphatidyl serine, phosphatidyl ethanolamine, and a fraction containing an inositol phosphatide. J. biol. Chem. 146: 35 1942;
6 Hicks N. D, Bonnin J. A. The behaviour of coagulation factors during anticoagulant therapy with special reference to the one-stage test as an index of therapy. Brit. J. Haemat. 05: 194 1959;
7 Johnson S. A, Caldwell M. J, Priest EMcCall. Effect of oral anticoagulant (marcoumar) on prothrombin and related components in blood coagulation. Circulation Res. 05: 252 1957;
8 Koller F. Antikoagulantien bei Herzkrankheiten. Schweiz, med. Wschr. 92: 769 1962;
9 Loeliger E. A. Über den Nachweis eines neuen Blutgerinnungsfaktors: Faktor VII. Thesis, Zürich 1952. Wien. Z. inn. Med. 03: 169 1952;
10 Loeliger E. A. Probleme der Antikoagulantienbehandlung in der Inneren Medizin. III. Hamburger Symposion über Blutgerinnung. Thrombos. Diathes. haemoorh. 05 (Suppl.) 46 1961;
11 Loeliger E. A, Hensen A. Substitution therapy in haemophilia B. Thrombos. Diathes. haemorrh. 06: 391 1961;
12 Loeliger E. A, van der Esch B, Mattern M. J. The turnover rate of prothrombin, factor VII and factor X in hypo-and hyperthyroidism and during fever (to be published.
13 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative determination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 03: 169 1951;
14 Owren P. A. Thrombotest. A new method for controlling anticoagulant therapy. Lancet 02: 754 1959;
15 Owren P. A. Critical study of tests for control of anticoagulant therapy. In: Wright I. S, Koller F, Beck E. Progress in coagulation. Thrombos. Diathes. haemorrh. 7 (Suppl.) 294 1962
16 Shanberge J. N. The effect of dicoumarol on certain factors of blood coagulation. J. Lab. clin. Med. 48: 218 1956;
17 Vermeulen H. J, ten Huinink S. ABokkel, Radhakishun K. S. Some observations on the coagulation defect during treatment with the anticoagulant “Sintrom”. Thrombos. Diathes. haemorrh. 03: 92 1959;
18 Walker W. Control of anticoagulant therapy: critical evaluation of control methods. In: Wright I. S, Koller F, Beck E. Progress in coagulation. Thrombos. Diathes. haemorrh. 7 (Suppl. 284) 1962
19 Zollikofer H, Schulthess P. v, Pugatsch I. Über eine neue Kontroll-methode der Antikoagulantientherapie. Helv. med. Acta. 25: 465 1958;